3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Renal Cell
3
Sarcoma, Clear Cell
2
Sarcoma
2
Neurofibrosarcoma
2
Nerve Sheath Neoplasms
2
Liposarcoma
2
Histiocytoma, Angiomatoid Fibrous
2
Granuloma, Plasma Cell
2
Fibrosarcoma
2
Dermatofibrosarcoma
2
Chondrosarcoma, Extraskeletal Myxoid
2
Vascular Neoplasms
1
Solitary Fibrous Tumors
1
Solid Neoplasm
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Perivascular Epithelioid Cell Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Adipose Tissue
1
Neoplasm Metastasis
1
Myoepithelioma
1
Liposarcoma, Myxoid
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Granular Cell Tumor
1
Interventions
Specimen Handling
43
pembrolizumab
42
Biopsy
36
Magnetic Resonance Spectroscopy
34
Paclitaxel
21
Carboplatin
21
Gemcitabine
20
Nivolumab
19
Irinotecan
17
Radiosurgery
15
Cisplatin
13
Taxes
11
Pemetrexed
11
Ipilimumab
11
Fluorouracil
11
Cetuximab
11
trastuzumab deruxtecan
10
olaparib
10
Leucovorin
10
130-nm albumin-bound paclitaxel
10
abemaciclib
9
Oxaliplatin
9
Cyclophosphamide
9
Capecitabine
9
Bevacizumab
9
palbociclib
8
durvalumab
8
Fulvestrant
8
X-Rays
7
Trastuzumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
pazopanib
×
90 days
×
Clear all
NCT01642017
2026-04-14
VOTRAGE
Institut Claudius Regaud
Phase 1
Terminated
18 enrolled